YANGTIAN BIOTECHNOLOGY LIMITED

四川杨天生物药业股份有限公司 (Sichuan Yangtian Biotechnology Co., Ltd.) is a modern pharmaceutical enterprise integrating production, sales, and research, established in October 2000 after approval from the Ministry of Foreign Trade and Economic Cooperation. Located in the Chengdu High-tech Industrial Development Zone, the company has been recognized as a “High-tech Enterprise” and a “Foreign Investment Advanced Technology Enterprise.” Yangtian Biopharma has a nationwide marketing network, with its product, Fufang Fengjia Weima Capsules, being the exclusive product in China. The product has been included in the latest edition of the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2022). During the COVID-19 pandemic, the company played a key role in providing essential supplies to Sichuan Province, and it was recommended by the Sichuan Provincial Health Commission and the Sichuan Provincial Medical Security Bureau for inclusion in the province's list of recommended drugs for COVID-19 prevention and treatment. The company aims to become a leading brand in cold medicine in China.